Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.57
NAS:ARRY's Cash-to-Debt is ranked lower than
76% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:ARRY: 1.57 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ARRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.67 Max: No Debt
Current: 1.57
Equity-to-Asset 0.11
NAS:ARRY's Equity-to-Asset is ranked lower than
91% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ARRY: 0.11 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ARRY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.55  Med: 0.22 Max: 0.93
Current: 0.11
-1.55
0.93
Piotroski F-Score: 5
Altman Z-Score: -0.63
Beneish M-Score: -3.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -61.17
NAS:ARRY's Operating Margin % is ranked higher than
55% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:ARRY: -61.17 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ARRY' s Operating Margin % Range Over the Past 10 Years
Min: -410.11  Med: -89.25 Max: 6.34
Current: -61.17
-410.11
6.34
Net Margin % -70.03
NAS:ARRY's Net Margin % is ranked higher than
52% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. NAS:ARRY: -70.03 )
Ranked among companies with meaningful Net Margin % only.
NAS:ARRY' s Net Margin % Range Over the Past 10 Years
Min: -511.63  Med: -116.55 Max: 18.05
Current: -70.03
-511.63
18.05
ROA % -52.93
NAS:ARRY's ROA % is ranked lower than
67% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. NAS:ARRY: -52.93 )
Ranked among companies with meaningful ROA % only.
NAS:ARRY' s ROA % Range Over the Past 10 Years
Min: -99.03  Med: -50.67 Max: 5.6
Current: -52.93
-99.03
5.6
ROC (Joel Greenblatt) % -1077.14
NAS:ARRY's ROC (Joel Greenblatt) % is ranked lower than
62% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. NAS:ARRY: -1077.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ARRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1397.54  Med: -273.72 Max: 297.05
Current: -1077.14
-1397.54
297.05
3-Year Revenue Growth Rate 14.30
NAS:ARRY's 3-Year Revenue Growth Rate is ranked higher than
67% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:ARRY: 14.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ARRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: -2.7 Max: 39.8
Current: 14.3
-35.9
39.8
3-Year EBITDA Growth Rate 9.40
NAS:ARRY's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. NAS:ARRY: 9.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ARRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.3  Med: 0.7 Max: 105.1
Current: 9.4
-66.3
105.1
3-Year EPS without NRI Growth Rate 4.50
NAS:ARRY's 3-Year EPS without NRI Growth Rate is ranked higher than
57% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:ARRY: 4.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ARRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.5  Med: 0.7 Max: 55.7
Current: 4.5
-50.5
55.7
GuruFocus has detected 2 Warning Signs with Array BioPharma Inc $NAS:ARRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ARRY's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:RGEN, NAS:FOLD, NYSE:EBS, NAS:INVA, NAS:CORT, NAS:AAAP, OTCPK:VNAPF, NAS:XLRN, NAS:DERM, NAS:BGNE, NAS:GBT, NAS:DBVT, OTCPK:BVNRY, NAS:LXRX, NAS:SRPT, NAS:ONCE, OTCPK:SOLTF, NAS:BPMC, NYSE:CBM, NAS:OMER » details
Traded in other countries:AR2.Germany,
Headquarter Location:USA
Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across various therapeutic areas. The Company's proprietary clinical programs include three cancer drugs, binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (partnered with AstraZeneca. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of oncology and other indications. The Company competes with companies that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.

Ratios

vs
industry
vs
history
PB Ratio 51.96
NAS:ARRY's PB Ratio is ranked lower than
98% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NAS:ARRY: 51.96 )
Ranked among companies with meaningful PB Ratio only.
NAS:ARRY' s PB Ratio Range Over the Past 10 Years
Min: 3.52  Med: 13.09 Max: 107.8
Current: 51.96
3.52
107.8
PS Ratio 8.17
NAS:ARRY's PS Ratio is ranked higher than
57% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. NAS:ARRY: 8.17 )
Ranked among companies with meaningful PS Ratio only.
NAS:ARRY' s PS Ratio Range Over the Past 10 Years
Min: 1.44  Med: 7.31 Max: 24.4
Current: 8.17
1.44
24.4
Current Ratio 3.47
NAS:ARRY's Current Ratio is ranked lower than
55% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NAS:ARRY: 3.47 )
Ranked among companies with meaningful Current Ratio only.
NAS:ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.96 Max: 7.86
Current: 3.47
0.81
7.86
Quick Ratio 3.47
NAS:ARRY's Quick Ratio is ranked lower than
52% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:ARRY: 3.47 )
Ranked among companies with meaningful Quick Ratio only.
NAS:ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 2.94 Max: 7.55
Current: 3.47
0.81
7.55
Days Sales Outstanding 74.03
NAS:ARRY's Days Sales Outstanding is ranked lower than
56% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. NAS:ARRY: 74.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
NAS:ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.06  Med: 47.09 Max: 497.21
Current: 74.03
2.06
497.21
Days Payable 92.10
NAS:ARRY's Days Payable is ranked higher than
68% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. NAS:ARRY: 92.10 )
Ranked among companies with meaningful Days Payable only.
NAS:ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 76.12 Max: 159.87
Current: 92.1
37.58
159.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.10
NAS:ARRY's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NAS:ARRY: -7.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NAS:ARRY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.3  Med: -11.8 Max: -4.2
Current: -7.1
-111.3
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 77.00
NAS:ARRY's Price-to-Net-Current-Asset-Value is ranked lower than
98% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. NAS:ARRY: 77.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NAS:ARRY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.24  Med: 6.29 Max: 82.55
Current: 77
2.24
82.55
Price-to-Tangible-Book 52.94
NAS:ARRY's Price-to-Tangible-Book is ranked lower than
98% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. NAS:ARRY: 52.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NAS:ARRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.14  Med: 4.33 Max: 102.93
Current: 52.94
1.14
102.93
Price-to-Median-PS-Value 1.12
NAS:ARRY's Price-to-Median-PS-Value is ranked lower than
65% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NAS:ARRY: 1.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NAS:ARRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.9 Max: 3.02
Current: 1.12
0.2
3.02
Earnings Yield (Greenblatt) % -7.30
NAS:ARRY's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. NAS:ARRY: -7.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NAS:ARRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.2  Med: -15.3 Max: 5.1
Current: -7.3
-95.2
5.1

More Statistics

Revenue (TTM) (Mil) $160.28
EPS (TTM) $ -0.73
Beta1.75
Short Percentage of Float18.60%
52-Week Range $3.10 - 13.40
Shares Outstanding (Mil)170.80

Analyst Estimate

Jun17 Jun18
Revenue (Mil $)
EPS ($) -0.81 -1.38
EPS without NRI ($) -0.81 -1.38
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}